Hidenori Akutsu is a director of the Department of Reproductive Medicine at the National Research Institute for Child Health and Development in Tokyo, Japan. He is a member of Expert Panel on Bioethics, Council for Science and Technology Innovation (CSTI) of Japan and also a Secretary of the Committee on Genome Editing Technology in Medical Sciences and Clinical Applications of the Science Council of Japan. His research explores mechanisms of preimplantation development and stem cell reprogramming. He has derived human embryonic stem cells in Japan.
Akutsu received his M.D. from Hirosaki University and completed his clinical training in obstetrics gynecology at Fukushima Medical University. He completed his Ph.D. at Fukushima Medical University School of Medicine.
Paula Amato, M.D., is Associate Professor of Obstetrics and Gynecology and Associate Scientist in the Center for Embryonic Cell and Gene Therapy at Oregon Health and Science University (OHSU). Amato is former chair of the Ethics Committee of the American Society for Reproductive Medicine. For the last decade, Amato has collaborated closely with Dr. Shoukhrat Mitalipov, Ph.D., at OHSU on novel germline gene therapy approaches to prevent the transmission of genetic diseases in humans.
Amato obtained her M.D. from the University of Toronto in Canada, where she also completed her OB/GYN residency. She subsequently completed a Fellowship in Reproductive Endocrinology and Infertility at the University of California, San Diego.
Maurizio Balistreri is Assistant Professor in Moral Philosophy at the Department of Philosophy and Educational Sciences, University of Turin. His main research interests involve metaethics, normative ethics, assisted human reproduction, human cloning, stem cells, genome editing, and future generations’ rights. Among his latest publications are: Sex Robot: Love in the Age of Machines (Fandango 2018); The Future of Human Reproduction (Fandango 2016); Human Cloning Before Dolly (Mimesis 2015); and SuperHumans. Etica and enhancement (2011).
David Baltimore* (NAS/NAM), Ph.D., former president, California Institute of Technology (1997-2006), is President Emeritus and the Robert Andrews Millikan Professor of Biology and one of the world's most influential biologists. He has contributed widely to the understanding of cancer, AIDS and the molecular basis of the human body's immune response and has profoundly influenced national science policy on such issues as the AIDS epidemic and research in genetic engineering. In 1975, he was awarded the Nobel Prize in Physiology or Medicine for his research into viral replication that provided the key to understanding the life cycle of retroviruses. His present research focuses on control of inflammatory and immune responses as well as on the use of gene therapy methods to treat HIV and cancer in a program called “Engineering Immunity.” In addition, he co-directs the Joint Center for Translational Medicine, an activity that joins Caltech and UCLA in a program to translate basic science discoveries into clinical realities.
Baltimore has played an important role in the development of American biotechnology since his involvement in the 1970s in the formation of Collaborative Genetics. He helped found other companies, most recently Calimmune and Immune Design and presently serves on the Board of Directors at several companies and nonprofits including the Broad Foundation and the Broad Institute, and Regulus Therapeutics. He is a scientific adviser to the Ragon Institute and Amgen. He is a science partner to the venture capital firm The Column Group and served as a director of the Swiss investment company BB Biotech. He is a past chair of the American Association of the Advancement of Science and a fellow of the American Association for Cancer Research. He is the 1999 recipient of the National Medal of Science and he has published more than 700 peer-reviewed articles.
Kevin G. Behrens is Associate Professor at the Steve Biko Center for Bioethics, University of the Witwatersrand, Johannesburg, South Africa, where he is the academic co-ordinator of Ph.D. studies. His research interests lie in the area of bioethics and environmental ethics. A major emphasis in his work is on applying African moral philosophical notions to ethical questions. He has published widely in international and national journals and is Editor-in-Chief of the African Journal of Business Ethics. He is a member of the Clinical Expert Advisory Panel of the South African Council of Medical Schemes.
Vence L. Bonham, J.D., is an Associate Investigator in the Social and Behavioral Research Branch of the National Human Genome Research Institute (NHGRI) at the National Institutes of Health. He leads the Health Disparities Genomics Unit, which conducts research that evaluates approaches to integrating new genomic knowledge and precision medicine into clinical settings without exacerbating inequities in healthcare delivery. Mr. Bonham also serves as the Senior Advisor to the NHGRI Director on Genomics and Health Disparities.
Dana Carroll is Distinguished Professor of Biochemistry at the University of Utah School of Medicine, where he has been on the faculty since 1975. He received his B.A. degree from Swarthmore College and a Ph.D. from the University of California, Berkeley. He did postdoctoral research with John Paul in Glasgow, Scotland and Donald Brown in Baltimore, Maryland, U.S.A. He served as co-chair and chair of the Department of Biochemistry between 1985 and 2009. He is considered a pioneer in the development and applications of genome editing with programmable nucleases. Carroll’s research group was the first to show that zinc-finger nucleases stimulate targeted mutagenesis and gene replacement in living cells and whole organisms. He received the Novitski Prize from the Genetics Society of America in 2012, was elected a Fellow of the American Association for the Advancement of Science in 2013, and was awarded the H.A. Sober Lectureship by the American Society for Biochemistry and Molecular Biology in 2014. Carroll is a member of the American Academy of Arts and Sciences and the U.S. National Academy of Sciences. He continues to pursue research with each of the current genome editing technologies – ZFNs, TALENs, and CRISPR-Cas.
Lot Chan studied pharmacy in London and public health in Hong Kong. He joined the Department of Health, Hong Kong Special Administrative Region Government, more than twenty years ago. Mr. Chan has worked in different posts under the Drug Office as well as the former Pharmaceutical Service of the Department of Health. He is currently the Chief Pharmacist who oversees the licensing and compliance of pharmaceutical traders, pharmacovigilance, and law enforcement of various drug-related regulations. Chan also oversees the development of the regulatory regime for advanced therapy products in Hong Kong.
Sarah Chan is a Chancellor’s Fellow working in interdisciplinary bioethics at the Usher Institute for Population Health Sciences and Informatics and Co-Director of the Mason Institute for Medicine, Life Sciences and Law, University of Edinburgh. Previously, from 2005 to 2015, she was a Research Fellow in bioethics at the University of Manchester, first at the Centre for Social Ethics and Policy and from 2008 the Institute for Science Ethics and Innovation. Chan’s research focuses on the ethics of new biomedical technologies, including stem cell and embryo research; reproductive medicine; synthetic biology; gene therapy and genetic modification; and human and animal enhancement. Her current work draws on these interests to explore the ethics of emerging modes of biomedicine at the interface of health care research, medical treatment, and consumer medicine including population-level health and genetic data research; the use of biomaterials in both research and treatment; and access to experimental treatments and medical innovation.
R. Alta Charo,* J.D., is the Warren P. Knowles Professor of Law and Bioethics, University of Wisconsin. Charo’s work has focused on reproductive technologies, research ethics, stem cell policy, drug safety, genetic engineering, and genome editing. Her federal government employment has included the congressional Office of Technology Assessment, the U.S. Agency for International Development, and the Food and Drug Administration. Professor Charo’s advisory committee service for the federal government includes the 1994 National Institutes of Health Human Embryo Research Panel, President Clinton's National Bioethics Advisory Commission (1996-2001), and President Obama’s HHS transition team (2008-2009).
Charo is a member of the U.S. National Academy of Medicine (NAM). At the U.S. National Academies, she is a member of the NAM Council and has been a member of the Board on Life Sciences, the Board on Population Health and Public Health Practice, and is, at present, a member of the Committee on Science, Technology, and Law as well as the Board on Health Sciences Policy. Charo has served on a number of study committees, including the Committee on Research Standards and Practices to Prevent Destructive Applications of Biotechnology; the Committee on Smallpox Vaccination Program Implementation; the Committee on the Future of Drug Safety; and the Committee on Mitochondrial Replacement Techniques. She also was a founding co-chair of the Forum on Regenerative Medicine and co-chaired the National Academies’ Human Embryonic Stem Cell Research Advisory Committee and, most recently, its Committee on Gene Editing Ethics and Policy.
Kathryn Song Eng Cheah is Jimmy and Emily Tang Professor in Molecular Genetics and Chair Professor of Biochemistry at the University of Hong Kong (HKU). A Malaysian by nationality, she graduated from the University of London (B.Sc.) and the University of Cambridge (Ph.D.) and was a postdoctoral fellow at the University of Manchester and the Imperial Cancer Research Fund. She began her career as a lecturer at the University of Hong Kong in 1983, where she later served as Head, Department of Biochemistry (1997-2009) and Director of the Centre for Reproduction, Development, and Growth (2004-09). Cheah’s research focuses on the functional genomics and the genetics of skeletal and inner ear development and their implication in human diseases.
Cheah was awarded a Croucher Foundation Senior Fellowship (2000) and is an elected fellow of the global science academy, The World Academy Sciences (TWAS). She was the founding president of the Hong Kong Society for Developmental Biology (HKSDB) (2004-2013); Hong Kong representative for Asia-Pacific Developmental Biology Network and the International Society of Developmental Biology; elected president of the International Society for Matrix Biology (2006-2008); and appointed Senior External Fellow of the University of Freiberg Institute of Advanced Studies (2011-2012). Currently Cheah is an elected member of the Board of Directors of the International Society of Differentiation (2012-2018); serves on the Hong Kong Advisory Board of the Gordon Research Conferences (GRC); and has recently been appointed as a member of the GRC Conference Evaluation Committee (2019-2025).
Cheah has served on the Editorial Boards of Development Growth & Differentiation, Matrix Biology (2006-2013), Annual Reviews of Genomics & Human Genetics (2012-2017), BioEssays (2009-2018) and as a Guest Associate Editor for PLoS Genetics (2013-2017). She was Asian Editor for Development Growth & Differentiation (2015-2016). Currently, she serves on the editorial boards of Nature Scientific Reports. She has been Associate Editor of Genesis since 2010. Cheah actively promotes public understanding of science through the organization of public lectures. She has organized 11 Croucher Foundation Advanced Study Institutes, served on the organizing/program committees of international symposia (e.g., Human Genome Meeting), and has chaired the Gordon Research Conference on Cartilage Biology and Pathology in 2011 and the HKSDB Symposium “From Embryology to Disease Mechanisms” in 2012.
Hervé Chneiweiss, a neurologist and neuroscientist, is Research Director at the CNRS (Centre National de la Recherche Scientifique). He studies molecular mechanisms involved in glial plasticity and underlying brain tumor development. First trained as a neurologist (movement disorders), Chneiweiss was involved in the neurogenetics of human diseases such as cerebellar ataxias. For the last 15 years his scientific work was dedicated to the biology of astrocytes, the molecular mechanisms underlying the plasticity of their phenotype and their roles in brain tumor origin and progression. Technical approaches include proteomics, metabolism, epigenetics, cell biology, animal models. He has published more than 150 original scientific articles. He is currently head of the research center Neuroscience Paris Seine – IBPS (CNRS/Inserm/Sorbonne University). Chneiweiss is also involved in bioethics, once the adviser for life sciences and bioethics to the French minister for research and technology (2000-02) and member of the national advisory ethic committee (CCNE, 2013-17), and presently head of the Inserm ethic committee and member of the International Bioethic Committee of UNESCO. He is among the founders and member of the board of the Association for Responsible Research and Innovation in Genome Editing (ARRIGE).
John Christodoulou is the Chair of Genomic Medicine, Department of Pediatrics, University of Melbourne, the Head of the Neurodevelopmental Genomics Research Group, and Director of the Genetics Research Theme at the Murdoch Childrens Research Institute in Melbourne, Australia. He graduated from the University of Sydney, and has formal qualifications in pediatrics, medical genetics and genetic pathology.
Christodoulou’s research interests include Rett syndrome and mitochondrial disorders, and he has a major research interest in the application of next generation sequencing (NGS) technologies in rare genetic disorders. He is the co-lead of the Australian Genomics Health Alliance, focusing on bringing NGS diagnostics into mainstream clinical practice in Australia.
Christodoulou is a past president of the Human Genetics Society of Australasia. In 2010, he became a Member of the General Division of the Order of Australia (AM) and in 2017 became a Fellow of the Australian Academy of Health & Medical Sciences.
Merlin Crossley trained or worked at the University of Melbourne, Oxford, Harvard, and Sydney before joining the University of New South Wales, Sydney, as Dean of Science in 2010. In 2016, he became Deputy Vice-Chancellor Education. He works in the area of gene regulation, has identified numerous new transcription factors, has been instrumental in uncovering the role of regulatory mutations associated with Hemophilia B Leyden (an unusual form of the condition that resolves after puberty), and has also deduced the mechanism of action of promoter mutations associated with the Hereditary Persistence of Fetal Hemoglobin. Editing in these naturally occurring mutations into blood stem cells is seen as a potential treatment for sickle cell disease and related disorders. As well as leading a laboratory, Crossley is an enthusiastic teacher and science communicator. He is or has served on the boards of the Australian Museum, Sydney Institute of Marine Science, Australian Science Media Centre, NewSouth Publishing, and is on the editorial board of The Conversation and BioEssays.Judith Daar is a Visiting Professor of Law at the University of California, Irvine School of Law and served as Interim Dean at Whittier Law School from 2016 to 2017. In addition to her law school affiliation, Professor Daar is a Clinical Professor of Medicine at the University of California, Irvine School of Medicine. She currently serves as Chair of the American Society for Reproductive Medicine Ethics Committee, a position she assumed in 2014. Her work in the intersection of law and medicine explores the impact of advances in science and technology on patients, physicians, and society, particularly in the realm of reproductive medicine. An expert on legal, ethical, and clinical aspects of reproductive medicine, Professor Daar has authored over 100 publications in the field covering a range of topics including human cloning, genetic testing of embryos, family formation through surrogacy and gamete donation, access to infertility care, and stem cell research. Her most recent book, The New Eugenics: Selective Breeding in an Era of Reproductive Technologies, was published by Yale University Press in 2017.
George Q. Daley,* M.D., Ph.D., is dean of the Faculty of Medicine and Caroline Shields Walker Professor of Medicine, Harvard Medical School. Daley trained in internal medicine at Massachusetts General Hospital, where he served as chief resident, and completed a clinical fellowship in hematology/oncology at Brigham and Women’s Hospital, Dana Farber Cancer Institute, and Boston Children’s Hospital. He was a founding executive committee member of the Harvard Stem Cell Institute, served as president of the International Society for Stem Cell Research (ISSCR, 2007-2008), and anchored the special task forces that produced the ISSCR Guidelines for Stem Cell Research and Clinical Translation (2006, 2008, 2016). As a graduate student with David Baltimore, Daley created the mouse model that proved the BCR/ABL oncogene causes human chronic myeloid leukemia (CML), work that validated BCR/ABL as a target for drug blockade and helped motivate the development of Gleevec®, a revolutionary magic-bullet chemotherapy that induces remissions in virtually every CML patient. Daley’s laboratory studies blood development from embryonic and induced pluripotent stem cells, with the goal of translating insights in stem cell biology into cellular therapies for degenerative, malignant, and genetic blood diseases.
Daley has been elected to the National Academy of Medicine, the American Society for Clinical Investigation, the American Association of Physicians, the American Academy of Arts and Sciences, and the American Association for the Advancement of Science. He was an inaugural winner of the NIH Director’s Pioneer Award, and has won the E. Donnall Thomas Prize of the American Society of Hematology. Daley received his A.B. magna cum laude from Harvard University, a Ph.D. in biology from MIT, and his M.D. summa cum laude from Harvard Medical School.
Guido de Wert is Professor of Biomedical Ethics at the Faculty of Health, Medicine, and Life Sciences, Maastricht University, The Netherlands. He chairs the Department of Health, Ethics and Society. His main research interests regard the ethics of genomic, reproductive and regenerative medicine.
De Wert was a member of the Health Council of the Netherlands for many years and is a member of both the Professional and Public Policy Committee (PPPC) of the European Society of Human Genetics (ESHG) and the Ethics Committee of the European Society of Human Reproduction and Embryology (ESHRE).
His publications include: De Wert G, Pennings G, Clarke A, et al. European Society of Human Genetics and the European Society of Human Reproduction and Embryology. “Human germline gene editing: Recommendations of ESHG and ESHRE.” Eur J Hum Genet 2018;26(4):445-449; and De Wert G, Heindryckx B, Pennings G, et al. European Society of Human Genetics and the European Society of Human Reproduction and Embryology. “Responsible innovation in human germline gene editing: Background document to the recommendations of ESHG and ESHRE.” Eur J Hum Genet. 2018;26(4):450-470.
Ames Dhai is Director of the Steve Biko Centre for Bioethics, Faculty of Health Sciences, University of the Witwatersrand and Honorary Professor in the College of Human and Health Sciences, Swansea University, UK. She established the Centre in 2007. It has local and international recognition as a leading Centre. She is a member of the Wits Senate Academic Freedom Committee and current chair of the University Forum. She serves on several policy making bodies in the country, including being a Past President of the South African Medical Association (SAMA), and the board of the recently established South African Health Products Regulatory Authority. She also serves as an expert advisor for the World Medical Association, the World Health Organization (WHO), and is on the WHO’s African Advisory Committee for Health Research. She has participated in activities of the U.S. Institute of Medicine and the U.S. National Academy of Sciences. Dhai is Editor-in-chief of the South African Journal of Bioethics and Law and Associate Editor of the South African Medical Journal. She can be credited with entrenching bioethics and human rights as an integral aspect of health sciences in South Africa. She is the recipient of several awards including SAMA Gender Acclaim Award (2012), the SAMA Certificate Award (2012) in honour of patriotism, courage and contribution made in the struggle for liberation of the medical profession and a joint recipient of the Vice-Chancellor’s Academic Citizenship Award (2017). Using an academic platform, Dhai has taken a lead in health advocacy and activism locally and internationally.
Jennifer Doudna,* Ph.D., is an internationally renowned professor of chemistry and molecular and cell biology, U.C. Berkeley. Doudna and her colleagues rocked the research world in 2012 by describing a simple way of editing the DNA of any organism using an RNA-guided protein found in bacteria. This technology, called CRISPR-Cas9, has opened the floodgates of possibility for human and non-human applications of gene editing, including assisting researchers in the fight against HIV, sickle cell disease, and muscular dystrophy. Doudna is an investigator with the Howard Hughes Medical Institute and a member of the National Academy of Sciences, the National Academy of Medicine, the National Academy of Inventors, and the American Academy of Arts and Sciences. She is also a foreign member of the Royal Society, and has received many other honors including the Breakthrough Prize in Life Sciences, the Heineken Prize, the BBVA Foundation Frontiers of Knowledge Award, and the Japan Prize. She is the co-author with Sam Sternberg of A Crack in Creation, a personal account of her research and the societal and ethical implications of gene editing.
Victor J. Dzau, M.D., is the President of the National Academy of Medicine (NAM), formerly the Institute of Medicine (IOM). In addition, he serves as Vice Chair of the National Research Council. Dzau is Chancellor Emeritus and James B. Duke Professor of Medicine at Duke University and the past President and CEO of the Duke University Health System. Previously, Dzau was the Hershey Professor of Theory and Practice of Medicine and Chairman of Medicine at Harvard Medical School’s Brigham and Women’s Hospital, as well as Chairman of the Department of Medicine at Stanford University.
Dzau is an internationally acclaimed leader and scientist whose work has improved health care in the United States and globally. His seminal work in cardiovascular medicine and genetics laid the foundation for the development of the class of lifesaving drugs known as ACE inhibitors, used globally to treat hypertension and heart failure. Dzau pioneered gene therapy for vascular disease and was the first to introduce DNA decoy molecules to block transcriptions in humans in vivo. His pioneering research in cardiac regeneration led to the Paracrine Hypothesis of stem cell action and his recent strategy of direct cardiac reprogramming using microRNA. He maintains an active NIH-funded research laboratory.
In his role as a leader in health care, Dzau has led efforts in innovation to improve health, including the development of the Duke Translational Medicine Institute, the Duke Global Health Institute, the Duke-National University of Singapore Graduate Medical School, and the Duke Institute for Health Innovation. He has served as a member of the Advisory Committee to the Director of the National Institutes of Health (NIH), chaired the NIH Cardiovascular Disease Advisory Committee and currently chairs the NIH Cardiovascular Stem Cell Biology and Translational Consortia. Currently, he is a member of the Board of the Singapore Health System, member of the Health Biomedical Sciences International Advisory Council of Singapore and Advisory Council of the Imperial College Health Partners, UK. He chairs the International Scientific Advisory Committee of the Qatar Genome Project, chairs the Scientific Boards of the Peter Munk Cardiac Center, University of Toronto and Institute of Cardiovascular and Medical Sciences, University of Glasgow. He was on the Canada Gairdner Award Medical Advisory Board and is now on the Board of Directors of the Gairdner Foundation. He served on the Board of Health Governors of the World Economic Forum and chaired its Global Agenda Council on Precision Medicine.
Since arriving at the National Academies, Dzau has designed and led important initiatives such as the Commission on a Global Health Risk Framework for the Future; the Human Genome Editing Initiative; and Vital Directions for Health and Health Care. The launch of the NAM Grand Challenge for Healthy Longevity represents his vision to inspire across disciplines and sectors to coalesce around a shared priority and audacious goal to advance health.
Among his many honors and recognitions are the Max Delbreck Medal from Charite, Humboldt and Max Planck, Germany, the Distinguished Scientist Award from the American Heart Association, Ellis Island Medal of Honor, and the Henry Freisen International Prize. In 2014, he received the Public Service Medal from the President of Singapore. He has been elected to the National Academy of Medicine, the American Academy of Arts and Sciences, the European Academy of Sciences and Arts, and Academia Sinica. He has received 15 honorary doctorates.
Beverley Francis-Gibson is President/CEO of the Sickle Cell Disease Association of America, Inc. (SCDAA).
Francis-Gibson previously served as the Executive Director of the National Alliance on Mental Illness (NAMI HC) of Howard County in Columbia, Maryland and has more than 25 years of experience serving non-profits and community foundations. She is immediate past chair of the Board of Directors of Maryland Nonprofits. She is a 2009 Leadership Premiere Graduate and previous Board member of Leadership Howard County. Francis-Gibson is currently co-delegate for the Behavioral Health Work Group; member of the Child Fatality Review Team; board member of The Clarion Call and a member of the Local Health Improvement Coalition. She is a member of the Sickle Cell Disease Coalition and the Sickle Cell Steering Committee. She also serves on the National Minority Quality Forum’s Sickle Cell Disease Working Group, and is a proud member of Delta Sigma Theta Sorority, Inc.
Francis-Gibson is the creator and co-facilitator of “Leadership Conversations” a quarterly gathering of nonprofit Executive Directors who share best practices, network and hear from engaging speakers on various topics. Currently, she mentors Executive Directors through her affiliation with the Association of Community Services.
She has been a dynamic instructor on fundraising, grant writing and philanthropy at Duke University’s Nonprofit Management Program and at the University of Chapel Hill in Durham and Chapel Hill, North Carolina, respectively. She has been a popular speaker and webinar presenter at the Maryland Governor’s Conference on Grant Making for several years.
Francis-Gibson brings her extensive nonprofit experience to SCDAA in the areas of management, grants, philanthropy, public speaking, fundraising/special events, advocacy and board development. Additionally, she brings her specialized expertise and exceptional professionalism to SCDAA and is excited to be joining the sickle cell family to help raise awareness of the disease across the country.
A native of St. Thomas, U.S. Virgin Islands, Francis-Gibson holds a B.A. in Public Relations and Communications and an M.A. in Industrial and Community Counseling from Eastern Kentucky University in Richmond, Kentucky.
Bärbel Friedrich studied biology at the University of Goettingen. After receiving her Ph.D. in microbiology in 1973, she worked as a post-doc at the Massachusetts Institute of Technology. In 1985, she was appointed Full Professor of Microbiology at the Free University of Berlin. From 1994 until her retirement in 2013, she held a chair for Microbiology at the Humboldt University Berlin. Her research focused on synthesis, structure and function of hydrogenases, protein-catalyzed assembly of metal co-factors and functional genetics of lithoautotrophic bacteria as documented in 200 original papers. From 2008 to 2018, she was director of the Alfried Krupp Institute for Advanced Studies in Greifswald. She is member of several scientific academies and research boards, including the council of the University of Vienna. From 1997 until 2003 she was Vice President of the German Science Foundation, and from 2005 to 2015 Vice President of the German National Academy of Sciences Leopoldina. She has received a number of prizes and honors, including the Arthur-Burkhardt-Prize, the Cross of Merit of the Federal Republic of Germany, and the Leopoldina Medal of Merit.
Mohammed Ghaly is Professor of Islam and Biomedical Ethics at the Research Center for Islamic Legislation & Ethics (CILE), College of Islamic Studies at Hamad Bin Khalifa University in Doha, Qatar. He has B.A. degree in Islamic Studies from Al-Azhar University (Egypt) and M.A. and Ph.D. degrees in the same specialization from Leiden University (the Netherlands). During the period 2007-2013, Ghaly was a faculty member at Leiden University.
The intersection of Islamic Ethics and biomedical sciences is Ghaly’s main specialization. He is the Editor-in-chief of the Journal of Islamic Ethics (published by Brill). Since 2011, Ghaly has been a faculty member at the Erasmus Mundus Program; the European Master of Bioethics, jointly organized by a number of European universities. Ghaly has lectured on Islamic bioethics at many universities worldwide including Imperial College London, Oxford University, University of Oslo, University of Chicago and Georgetown University. During the academic year 2014-2015, he was Visiting Researcher of the Kennedy Institute of Ethics at Georgetown University, USA. In 2017-2018, he was a Visiting Scholar of the School of Anthropology and Museum Ethnology at the University of Oxford.
Besides his book Islam and Disability: Perspectives in Theology and Jurisprudence (Routledge, 2010) and the edited volume Islamic Perspectives on the Principles of Biomedical Ethics (Imperial College & World Scientific, 2016), Ghaly is the single author of about thirty peer-reviewed publications and serves on the editorial board of a number of academic journals. He is also the Lead Principal Investigator (LPI) and research consultant of a number of funded research projects.
Charles A. Gersbach is the Rooney Family Associate Professor at Duke University in the Departments of Biomedical Engineering and Orthopaedic Surgery, an Investigator in the Duke Center for Genomic and Computational Biology, and Director of the Duke Center for Biomolecular and Tissue Engineering. His research interests are in genome and epigenome editing, gene therapy, regenerative medicine, biomolecular and cellular engineering, synthetic biology, and genomics. Gersbach’s work has been recognized through awards including the National Institutes of Health Director’s New Innovator Award, the National Science Foundation CAREER Award, the Outstanding New Investigator Award from the American Society of Gene and Cell Therapy, the Allen Distinguished Investigator award, and induction as a Fellow of the American Institute for Medical and Biological Engineering.
Andy Greenfield has been a program leader in the Mammalian Genetics Unit at the Medical Research Council’s Harwell Institute since 1996. His research centers around the broad topic of how genes (and genomes) regulate embryonic development and how errors in developmental processes result in disease. His team focuses on the molecular genetics of sex determination – how a fetus develops testes or ovaries - using the mouse as a model genetic system for investigating disorders/differences of sex development (DSD). He uses genome editing in his research.
Since 2009, he has been a member of the Human Fertilisation & Embryology Authority (HFEA), the UK regulator of IVF clinics and human embryo research, and has chaired its License Committee since 2014. In 2016, this committee licensed the first UK use of CRISPR/Cas9 genome editing technology in human research embryos. Greenfield also chaired the two most recent expert panel assessments of the safety and efficacy of mitochondrial donation (mitochondrial replacement) techniques, in 2014 and 2016. These reports were integral parts of the process that resulted in clinical use of mitochondrial donation becoming lawful in the UK. Greenfield is a member of the Nuffield Council on Bioethics and chaired its 2016 working group that examined ethical issues surrounding the use of genome editing in a variety of contexts.
Yuko Harayama is a former Executive Member of the Council for Science and Technology Policy, Cabinet Office of Japan. She is the former Deputy Director of the Directorate for Science, Technology and Innovation, Organisation for Economic Co-operation and Development. Harayama is a Legion D’Honneur recipient (Chevalier) and was awarded honorary doctorate from the University of Neuchâtel. Previously, she was professor in the Department of Management Science and Technology at the Graduate School of Engineering of Tohoku University. She holds a Ph.D. in education sciences and a Ph.D. in economics, both from the University of Geneva.
Jiankui He is an associate professor at Southern University of Science and Technology at Shenzhen, China. He’s research focuses on genome sequencing technology, bioinformatics, and genome editing. His group has developed a single molecule genome sequencer, which can sequence the human without PCR amplification. He studied the CRISPR in bacteria immunity in 2009, and he is now focusing on improving the efficacy and safety of CRISPR-cas9 genome editing for therapeutics application. He was elected as “1000 Talents Program” experts in 2017. He received his Ph.D. at Rice University in Houston, Texas, and worked as postdoctoral research fellow in Stephen Quake lab at Stanford University.
R. Rodney Howell, M.D., is Professor of Pediatrics and Chairman Emeritus and a member of the Hussman Institute for Human Genomics at the Miller School of Medicine of the University of Miami. He is certified by both the American Board of Pediatrics, and the American Board of Medical Genetics. He has long been active in research into rare genetic diseases. In 2015, Howell was the first recipient of the Advocacy Award from the American Society of Human Genetics for his excellence and achievement in applications of human genetics for the common good.
As Senior Advisor to the Director of the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health from 2004-2011, Howell focused on the Institute’s research efforts in newborn screening. As founding chair of the U.S. congressionally-mandated Secretary’s Advisory Committee of Heritable Disorders in Newborns and Children (2004-2011), his committee advised the Secretary of the U.S. Department of Health and Human Services on issues concerning genetic testing in children, focusing on newborn screening.
Howell has served the major private funding agency for neuromuscular research in the United States, the Muscular Dystrophy Association, in many capacities including as chairman of its board of directors since 2007.
Junjiu Huang, Ph.D., is Professor and Vice Dean of School of Life Sciences at Sun Yat-sen University. Huang received his Ph.D. in Cell Biology from Sun Yat-sen University, Guangzhou, China, in 2009. He was appointed a Professor at Sun Yat-sen University in 2016. His major areas of research interest include: 1) the mechanism of cell senescence and regeneration; 2) the mechanism of implantation embryo development in mammals. Huang invented the use of Piezo micromanipulation to inject mESC into four- or eight-cell embryos to produce F0 ESC-mice in 2008. He published the world’s first report of human embryos altered by gene editing using CRISPR/Cas9 and was mentioned in “365 days: Nature’s 10” in 2015. Huang also the first one to correct the β-thalassemia mutant HBB −28 (A>G) by cytidine base editor in human embryos, which was mentioned in “2017 in news: The science events that shaped the year” in Nature. Huang has published more than 40 research articles in journals such as Molecular Cell, Cell Research, Stem Cells, and Protein Cell.
Xingxu Huang, Ph.D., is a professor in the School of Life Science and Technology, ShanghaiTech University. His research interests focus on developing genome editing approaches to engineer cells and animals for therapeutic purpose. He is one of the first scientists to achieve CRISPR-mediated genome editing in non-human primates and primary human T cells. Currently, he is developing and applying CRISPR/Cas9 for precise genome editing in T cell therapy and genetic disease treatment.
J. Benjamin Hurlbut, Ph.D., is Associate Professor of Biology and Society in the School of Life Sciences at Arizona State University. He is trained in science and technology studies (STS) with a focus on the history of the modern biomedical and life sciences. His research lies at the intersection of STS, bioethics and political theory. Hurlbut studies the changing relationships between science, politics, and law in the governance of biomedical research and innovation, examining the interplay of science and technology with notions of democracy, religious and moral pluralism, and public reason. He is the author of Experiments in Democracy: Human Embryo Research and the Politics of Bioethics (Columbia University Press, 2017) as well as numerous articles and book chapters. He received an A.B. in Classics from Stanford University and a Ph.D. in the History of Science from Harvard University. He was a postdoctoral fellow in the program on Science, Technology and Society at the Harvard Kennedy School.
Richard O. Hynes is a Daniel K. Ludwig Professor for Cancer Research at the Massachusetts Institute of Technology (MIT). He received his bachelor's and master’s degrees in biochemistry from the University of Cambridge, England, and his doctorate in biology from MIT in 1971. After postdoctoral work at the Imperial Cancer Research Fund in London, where he initiated his work on cell adhesion, he returned to MIT as a faculty member. Hynes is a Fellow of the Royal Society of London, the American Academy of Arts and Sciences, and the American Association for the Advancement of Science, and a member of the U.S. National Academy of Sciences and the U.S. National Academy of Medicine. He has received the Canada Gairdner International Award, the Robert J. and Claire Pasarow Foundation Medical Research Award, the Earl P. Benditt Award from the North American Vascular Biology Organization, and the E.B. Wilson Medal from the American Society for Cell Biology (ASCB). He previously headed MIT’s Biology Department, and served for 10 years as director of the MIT Center for Cancer Research. In 2014, he was named a Fellow of the American Association for Cancer Research Academy, and in 2016, an ASCB Fellow. He is currently on the Cold Spring Harbor Cancer Center Advisory Committee, the MGH Executive Committee on Research, the Rosenstiel Award Selection Committee, the Coalition for the Life Sciences, the Genentech Scientific Resource Board, and the Amgen Research Trends and Emerging Technologies Advisory Board.
Tetsuya Ishii is a professor at the Office of Health and Safety, Hokkaido University, Japan. His interests are the ethics of genetic engineering, stem cells, and reproductive medicine. Ishii was a speaker at the First International Summit on Human Genome Editing in Washington, DC in 2015.
Maria Jasin obtained a Ph.D. from the Massachusetts Institute of Technology and was a postdoctoral fellow at the University of Zürich and at Stanford University. Her lab at Memorial Sloan Kettering Cancer Center performed the first gene editing experiment, expressing a rare-cutting endonuclease to generate a DNA double-strand break (DSB) in the mammalian genome and developing genetic and molecular assays to identify DSB repair events. These experiments established a crucial role for both homologous recombination, also called homology-directed repair (HDR), and nonhomologous end-joining (NHEJ) in DSB repair: A DSB repaired by NHEJ leads to a variety of mutations in the genome, while a DSB repaired by HDR leads to a predetermined modification. With the approaches established in the lab, the breast cancer suppressors BRCA1 and BRCA2 were determined to be crucial for HDR repair, thus implicating HDR as a tumor suppression mechanism. The lab also has a major effort directed at understanding the generation and repair of programmed DSBs during meiotic progression which are essential for genome transmission. Jasin is a member of the U.S. National Academy of Sciences and U.S. National Academy of Medicine, and of the American Academy of Arts and Sciences.
Jeffrey Kahn is the Andreas C. Dracopoulos Director of the Johns Hopkins Berman Institute of Bioethics, and the Levi Professor of Bioethics and Public Policy. He is also Professor in the Department of Health Policy and Management in the Johns Hopkins University Bloomberg School of Public Health. His research interests include the ethics of research, ethics and public health, and ethics and emerging biomedical technologies. He speaks widely both in the U.S. and abroad and has published four books and over 125 articles in the bioethics and medical literature, and is currently co-PI for the Johns Hopkins Center of Excellence in Ethics and Policy Research on Genomics and Infectious Disease (NIH-NHGRI). He is an elected member of the National Academy of Medicine and Fellow of the Hastings Center, and has chaired or served on committees and panels for the National Institutes of Health, the Centers for Disease Control, and the Institute of Medicine/National Academy of Medicine, where he is currently chair of the Board on Health Sciences Policy. His education includes a BA in microbiology (UCLA, 1983), M.P.H. (Johns Hopkins, 1988), and Ph.D. in philosophy (Georgetown, 1989).
Kazuto Kato,* Ph.D., is Professor of Biomedical Ethics and Public Policy at the Graduate School of Medicine, Osaka University. Kato has a Ph.D. degree in developmental biology from Kyoto University. After finishing postdoctoral research at the University of Cambridge with Sir John Gurdon, he started to work on ethical and social issues related to life sciences. Kato is currently specializing in biomedical ethics, research governance and patient engagement in medical research.
Kato has served as a member of various international projects and academic societies to include the Ethics Committee of the Human Genome Organization (currently, Committee on Ethics, Law, and Society); the Ethics and Governance Committee of the International Cancer Genome Consortium; the Ethics Committee of the International Society for Stem Cell Research; and the Steering Committee of the Global Alliance for Genomics and Health. Currently, he is also the leader of the ELSI 2.0 network, which facilitates global collaborations of researchers on ELSI (Ethical, Legal, and Social Implications). In 2010, he was appointed a member of the Expert Panel on Bioethics of the Council for Science, Technology, and Innovation in Japan’s Cabinet Office. The panel has been working on the ethical and social issues of human genome editing technology since 2015.
Jin-Soo Kim,* Ph.D., is an entrepreneur and chemist-turned-biologist. He graduated from Seoul National University in 1987 with a major in chemistry. He then earned a master’s degree in chemistry from Seoul National University in 1989 and a Ph.D. in biochemistry from the University of Wisconsin, Madison in 1994. After postdoctoral training at Howard Hughes Medical Institute/Massachusetts Institute of Technology, he returned to Seoul in 1997 to serve as principal investigator at Samsung Biomedical Research Institute. He co-founded a biotechnology company, ToolGen Inc., focused on zinc finger technology and genome editing in 1999, and served as CEO and CSO for the subsequent six years. He joined the faculty of the department of chemistry at Seoul National University in 2005 and now serves as director of Center for Genome Engineering at Institute for Basic Science. He has published over 150 articles and filed 50 patent applications, mostly in the field of gene regulation and genome editing.
Throughout his independent scientific career since 1997, Kim has been developing tools for genome editing, a method now used widely in biomedical research, biotechnology, and medicine. The broad interest in this rapidly evolving and expanding technology among researchers is highlighted by the choice of genome editing as Method of the Year 2011 by Nature Methods and Breakthrough of the Year 2015 by Science. Genome editing in cultured cells, animals, and plants is catalyzed by programmable nucleases that cleave chromosomal DNA in a targeted manner. His group has developed and improved three different types of programmable nucleases, namely, zinc finger nucleases (ZFNs), TAL effector nucleases (TALENs), and RNA-guided endonucleases derived from CRISPR-Cas9 adaptive immune systems in prokaryotes. The Kim group was one of the first to report on targeted genome modifications in human cells using CRISPR-Cas9 in January 2013. Since then, Kim has developed methods known as Cas9/Cpf1/Base Editor ribonucleoprotein (RNP) delivery and Digenome-seq for minimizing and assessing, respectively, genome-wide CRISPR off-target effects, and has applied CRISPR technology to human stem cells and embryos, animals, and plants, offering great potential for broad applications in medicine and biotechnology. These tools are now used for genome editing in thousands of labs all around the world.
Ock-Joo Kim, M.D., Ph.D., a graduate of the Seoul National University College of Medicine, trained in biomedical ethics and medical history in University of Minnesota, Harvard University and Western IRB. Kim is Professor and Chair of the Department of Medical History and Medical Humanities, Seoul National University College of Medicine. From 2002 to 2011, she was a member and the Chair of the Ethics Committee of the Korean Stem Cell Center, while leading the ELSI project in stem cell research in Korea.
In collaboration with various governmental agencies and academia, Kim has worked on rebuilding the research ethics system and promoting research ethics education in Korea. As an expert in biomedical research ethics, she participated in the operation of National Bioethics Policy Institute and implementation and revision of Bioethics and Safety Act which governs embryo and genetic research. She is currently the director of the Center for Human Research Protection at the Seoul National University Hospital and a member of International Bioethics Committee at UNESCO. She is an author of books and papers on biomedical ethics including stem cell research and ethics of gene editing.
Eben Kirksey is an anthropologist who studies the interplay of nature and culture. He has published two books with Duke University Press — Freedom in Entangled Worlds (2012) and Emergent Ecologies (2015)—as well as over 25 peer reviewed articles and book chapters. Currently he is Associate Professor at Deakin University in Melbourne, Australia. Princeton University hosted Kirksey as the 2015-2016 Currie C. and Thomas A. Barron Visiting Professor. He was a Marshall Scholar at the University of Oxford and a National Science Foundation Postdoctoral Fellow at the University of Pittsburgh.
Satoshi Kodama’s background is moral and political philosophy. He graduated from Kyoto University and worked as a lecturer at the Department of Medical Ethics in the University of Tokyo Graduate School of Medicine from 2003 to 2011. He currently is Associate Professor of Ethics at Kyoto University Graduate School of Letters. His research interests include moral theory (utilitarianism), moral methodology (the role of intuition in moral reasoning), resource allocation, and public health ethics. He has written textbooks on biomedical ethics both in Japanese and English. His published books include Utility and Intuition (in Japanese, 2011), and An Introduction to Utilitarianism (in Japanese, 2013).
Carrie Lam, GBM, GBS, joined the Administrative Service of the Hong Kong Government in August 1980 and rose to the rank of Administrative Officer Staff Grade A1 in September 2006. She became a Principal Official on July 1, 2007, when she was appointed Secretary for Development. She was appointed Chief Secretary for Administration on July 1, 2012.
Mrs. Lam has served the public for more than 36 years in 20 public service positions including Director of Social Welfare, Permanent Secretary for Housing, Planning and Lands (Planning and Lands), Director-General of the Hong Kong Economic and Trade Office in London, Permanent Secretary for Home Affairs, Secretary for Development and Chief Secretary for Administration.
Mrs. Lam was elected as the Fifth-Term Chief Executive of the Hong Kong Special Administrative Region on March 26, 2017, and was officially appointed to this position by the Central People’s Government on March 31, 2017 to assume office on July 1, 2017.
Mrs. Lam is married and has two sons.
David R. Liu is the Richard Merkin Professor, Director of the Merkin Institute of Transformative Technologies in Healthcare, and Vice-Chair of the Faculty at the Broad Institute of Harvard and MIT; Professor of Chemistry and Chemical Biology at Harvard University; and Howard Hughes Medical Institute Investigator. Liu graduated first in his class at Harvard in 1994. He performed organic and bioorganic chemistry research on sterol biosynthesis under Professor E. J. Corey’s guidance as an undergraduate. During his Ph.D. research with Professor Peter Schultz at U. C. Berkeley, Liu initiated the first general effort to expand the genetic code in living cells. He earned his Ph.D. in 1999 and became Assistant Professor of Chemistry and Chemical Biology at Harvard University in the same year. He was promoted to Associate Professor in 2003 and to Full Professor in 2005. Liu became a Howard Hughes Medical Institute Investigator in 2005 and joined the JASONs, academic science advisors to the U.S. government, in 2009. Liu has earned several university-wide distinctions for teaching at Harvard, including the Joseph R. Levenson Memorial Teaching Prize, the Roslyn Abramson Award, and a Harvard College professorship. Liu has published more than 150 papers and is the holder of more than 50 patents. His research accomplishments have earned distinctions including the Ronald Breslow Award for Biomimetic Chemistry, the American Chemical Society Pure Chemistry Award, the Arthur C. Cope Young Scholar Award, and awards from the Sloan Foundation, Beckman Foundation, NSF CAREER Program, and Searle Scholars Program. In 2016, he was named one of the Top 20 Translational Researchers in the world by Nature Biotechnology and in 2017 was named to the Nature’s 10 researchers in world and to the Foreign Policy Leading Global Thinkers. Liu’s research integrates chemistry and evolution to illuminate biology and enable next-generation therapeutics. His major research interests include the engineering, evolution, and in vivo delivery of genome editing proteins such as base editors to study and treat genetic diseases; the evolution of proteins with novel therapeutic potential using phage-assisted continuous evolution (PACE); and the discovery of bioactive synthetic small molecules and synthetic polymers using DNA-templated organic synthesis and DNA-encoded libraries. Base editing (named one of four 2017 Breakthrough of the Year finalists by Science), PACE, and DNA-templated synthesis are three examples of technologies pioneered in his laboratory. He is the scientific founder or co-founder of five biotechnology and therapeutics companies, including Ensemble Therapeutics, Permeon Biologics, Editas Medicine, Pairwise Plants, and Beam Therapeutics.
Y. M. Dennis Lo is the Director of the Li Ka Shing Institute of Health Sciences and the Chairman of the Department of Chemical Pathology at The Chinese University of Hong Kong (CUHK). Lo received his Bachelor of Arts degree from the University of Cambridge, UK, and his Doctor of Medicine and Doctor of Philosophy degrees from the University of Oxford, UK. He returned to Hong Kong in 1997. In the same year, he reported, for the first time, the presence of cell-free fetal DNA in maternal plasma and has since pioneered its use for noninvasive prenatal testing. He has also seen the similarities between circulating DNA analysis for prenatal testing and cancer detection and has pushed forward the liquid biopsies of cancer. He has made particular contribution in the non-invasive detection of nasopharyngeal carcinoma. This work has demonstrated many of the fundamental characteristics and applications of circulating tumor DNA in plasma. In recognition of his work, Lo received the Future Science Prize in Life Science in 2016 and has been elected as a Fellow of the Royal Society in the UK and as a Foreign Associate of the U.S. National Academy of Sciences.
Angelo Lombardo obtained his Ph.D. in Cellular and Molecular Biology in 2011 from the Vita-Salute San Raffaele University (UniSR; Milan, IT) working on the development of innovative gene therapy approaches based on targeted genome editing. His early studies were the first to report genome editing in clinically relevant cell types, including pluripotent and hematopoietic stem cells. His contribution to the field extends to the identification of the human AAVS1 locus as a genomic safe harbor for transgenesis and the development of pioneering strategies to profile the specificity of artificial nucleases. Since 2013, Lombardo has been Assistant Professor at UniSR and, since 2015, Group Leader at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget; Milan, IT). His team has recently developed a novel modality of gene therapy that exploits targeted epigenome editing to permanently silence gene expression. Lombardo has published >25 articles in peer-reviewed journals, and he is inventor on several patent applications related to these publications. He has received numerous prestigious awards, including the Young Investigator Award from the European Society of Gene and Cells Therapy. He has been repeatedly invited as plenary speaker at top international meetings.
Robin Lovell-Badge* (FRS), Ph.D., is senior group leader at The Francis Crick Institute.
Lovell-Badge has had long-standing interests in the biology of stem cells, in how genes work in the context of embryo development, and how decisions of cell fate are made. Major themes of his current work include sex determination, development of the nervous system and pituitary, and the biology of stem cells within these systems and in the early embryo. He is also very active in both public engagement and policy work, notably around stem cells, genetics, human embryo and animal research, and in ways science is regulated and disseminated.
He was elected a member of EMBO in 1993, a fellow of the Academy of Medical Sciences in 1999, and a fellow of the Royal Society in 2001. He has received the Louis Jeantet Prize for Medicine (1995), the Amory Prize (Awarded by the American Academy of Arts and Sciences) (1996), the Feldberg Foundation Prize (2008), and the Waddington Medal of the British Society for Developmental Biology (2010). He was made a CBE in the 2018 New Year’s Honours. He is also a special visiting professor at the University of Hong Kong (2009-2021) and the president of the Institute of Animal Technologists.
Lovell-Badge obtained his B.Sc. in zoology in 1975 and his Ph.D. in embryology in 1978, both at University College London.
Tamra Maree Lysaght is Director of Research and Phase Director of the Health ethics, Law and Professionalism (HeLP) program at the Yong Loo Lin School of Medicine at the Centre for Biomedical Ethics, National University of Singapore. Lysaght has expertise in empirical bioethics and experience in using both qualitative and quantitative research methods to address normative questions pertaining to emergent biotechnologies and the biomedical sciences. Her work focuses on emerging health and biomedical technologies, including stem cell research and regenerative medicine, precision medicine and genomics, gene editing and AI in healthcare. She is currently a member of the AI and Data Ethics Advisory Council convened under the Infocomm Media Development Authority and Vice-Chair of the Committee for Ethics, Law and Society of the Human Genome Organization. She is also funded by the Singapore Social Science Research Council to investigate trustworthy governance models for sharing health-related data.
Pauline McCormack is Senior Lecturer at PEALS Research Centre, Newcastle University with degrees in Classics, Computing Science and a doctorate in Education. She is a medical sociologist committed to participatory approaches and the inclusion of patient and publics in research governance and design. Her interests include social and ethical issues in genomics; translational medicine; regulation of medical devices; and patient experiences of medical technologies. McCormack works closely with the rare disease community and has empirical experience in a number of large, international rare disease and genomics projects including TREAT- NMD and RD-Connect.
McCormack co-leads the Genomics England Partnership on Patient Involvement, sits on the IRDiRC taskforce on Barriers to Patient Participation, is a European Commission expert reviewer, and has served as academic specialist for the Nuffield Council on Bioethics and the European Neuromuscular Centre.
María de Jesús Medina Arellano is a qualified lawyer who graduated from the Autonomous University of Nayarit (UAN), Mexico in 2004. After finishing her degree, she decided to move to Mexico City to carry on her master’s studies in the Philosophy of Law. In January 2008 she graduated with the equivalent of an MPhil (with honours) from the Postgraduate Law Division at the National Autonomous University of Mexico (UNAM). During her postgraduate degree she focused on the emerging paradigm of Health Law and Human Rights in Mexico. In December 2008 she was recognised as the Young Academic Talent of the Year, an award granted by the Nayarit Government in Mexico. In 2010, Medina Arellano was awarded the UNAM-Alfonso Caso silver medal for outstanding achievement, as the best postgraduate student of the 2008 class in the area of social sciences. She was a recipient of a graduate “excellence grant” to pursue her master’s and doctoral studies from the Mexican Council for Science and Technology and Ministry of Education (CONACyT)/ Ministry of Education (SEP) and the Autonomous University of NAYARIT (UAN). Medina Arellano was also granted the University of Manchester ORS award and School of Law contribution to tuition fees for the second and third year of her Ph.D. in bioethics and medical jurisprudence. She obtained her Ph.D. in bioethics and medical jurisprudence in July 2012 from the School of Law (Centre for Social Ethics and Policy and the Institute for Science, Ethics and Innovation) at the University of Manchester. Her Ph.D. research focused in the regulation of stem cell research in developing countries (Mexico as a case study) under the supervision of Dr. David Gurnham, Dr. Sarah Devaney, Dr. Anne-Maree Farrell and John Harris. From 2013-2014 Medina Arellano worked as Deputy of the Judicial School in the Local Court of Justice in Nayarit. Since September 2014, she has been a full time senior researcher at the Legal Research Institute in the National Autonomous University of Mexico (UNAM). She is also a researcher, level 1, in Mexico’s CONACyT, a member of Hinxton International Group, and a member of the Mexican Society for Stem Cell Research.
Currently, Medina Arellano is the Deputy of the College of Bioethics (a civil association that gathers scientist and physicians working in the area of bioethics from practical and academic perspectives).
Jennifer Merchant,* Ph.D., is a professor of Anglo-American legal and political institutions, Université de Paris II (Panthéon-Assas). She is a leading researcher in bioethical issues of comparative public policy with expertise in North American and European policy, and politics and regulation of medical technologies involving human reproduction. She is also an expert in French law and politics on embryo research and assisted reproductive technology. Her academic interests include comparative public policy, reproduction, bioethics, civil society, science and government. Merchant is a member of the French National University Institute, the Center for the Study of Research of Administrative and Political Sciences, the Ethics Committee of the French National Institute of Health and Medical Research, and the International Network on Feminist Approaches to Bioethics (FAB) Association as well as FAB Country Representative. She has been Co-editor-in-chief of the international Tocqueville Review/Revue Tocqueville since 2001. She has been a member of the Global Ethics Observatory of UNESCO since 2005. She served on the U.S. National Academies of Sciences, Engineering, and Medicines’ human genome editing working committee from 2015-2017, and in 2016, with her European colleagues, launched the ARRIGE (Association for Responsible Research and Innovation in Genome Editing). She currently serves on its board.
Merchant received her Ph.D. degree in political sciences from the Institut d'études politiques de Paris.
Anna Middleton is the Founder and Head of the Society and Ethics Research group at the Wellcome Genome Campus. She is also a Professor/Affiliate Lecturer, Faculty of Education, University of Cambridge. She is a creative social sciences researcher with expertise in public understanding of genomics. She is passionate about delivering research that has real practical value and creates films and materials to explain genomics to public audiences. Middleton is involved in the genetic counselling profession internationally and is current chair of the Association of Genetic Nurses and Counsellors. She co-wrote and co-leads two modules of the University of Cambridge MSt Genomic Medicine course and co-created the first World Congress on Genetic Counselling.
Middleton’s current research focuses on: 1) international lay public attitudes towards anonymised DNA data being a part of Big Data (Your DNA, Your Say); 2) use of films in the NHS with patients to explain genomics as part of genetic counselling (Music of Life); and 3) a collaboration with Theatre of Debate to explore public attitudes toward the expectation of doctors to share relatives’ genetic results with others.
Peter Mills is Assistant Director at the UK’s Nuffield Council on Bioethics, an independent body that examines and reports on ethical issues in biology and medicine. He has previously held positions at the Human Fertilisation & Embryology Authority (HFEA) and the UK Department of Health and, at various times, has been head of the Human Genetics Commission Secretariat, a UK representative on the Council of Europe Bioethics Committee (DH-BIO) and a delegate to the UNESCO Intergovernmental Bioethics Committee. Mills read PPE at Trinity College, Oxford, and obtained a Ph.D. in philosophy from the University of Warwick. Since then, his interests have ranged across the fields of assisted conception, human genomics, biotechnology and data science, but they have always been situated at the intersection of science, ethics and public policy. Recently he has directed the Nuffield Council’s work program on genome editing, leading to the publication of the reports Genome Editing: An Ethical Review (2016) and Genome Editing and Human Reproduction: Social and Ethical Issues (2018).
Associate Professor Megan Munsie is Deputy Director of the University of Melbourne’s Centre for Stem Cell Systems within the School of Biomedical Sciences and also heads of the Engagement, Ethics and Policy Unit of the Australian Government funded Stem Cells Australia initiative. Over the course of her 20 year career in stem cell research Munsie has combined her scientific expertise – gained through working in academia and industry – with a deep understanding of the issues associated stem cell research and its clinical translation. She has co-authored numerous educational resources for the public, health and educational professionals; contributed to the development of policy at a domestic and international level; is a member of several international multidisciplinary research teams exploring impact of stem cell research and regularly provides advice and information to Australian patient advocacy groups and community members on stem cell science and associated issues. In 2018, Munsie was awarded the Public Service Award from the International Society for Stem Cell Research (ISSCR) in recognition of her public outreach and policy advocacy in stem cell science and is currently the chair of the ISSCR Ethics Committee.
Indira Nath,* M.D., Ph.D., is visiting professor at the Bio-Support Unit of the Department of Biotechnology, All India Institute of Medical Sciences (AIIMS); and is the former Raja Ramanna Fellow and Emeritus Professor, National Institute of Pathology in New Delhi. She received an MBBS (Bachelor of Medicine/Bachelor of Surgery) and M.D. in pathology from AIIMS, and later served on the AIIMS faculty, making pioneering contributions to immunology of infectious diseases with special interest in human leprosy. She mentored many M.Biotech, M.D., and Ph.D. students and contributes to education, medical, and science policies and women scientists' issues at national and international levels. She is the chair for Health and Wellbeing in Changing Urban Environment, a program of the International Council of Science; member of the InterAcademy Panel for Ethics; and was co-chair for the InterAcademy Panel-InterAcademy Council project on research integrity. She has been a member of the Scientific Advisory Committee to the Cabinet, Foreign Secretary, Indian National Science Academy (1995-1997); council member (1992-1994 and 1998-2006) and vice president (2001-2003) of the Indian Academy of Sciences, Bangalore; and chairperson, the Women Scientists Programme, Department of Science and Technology, Government of India (2003).
Nath has received several awards, notably Padma Shri; Chevalier Ordre National du Merite, France; Silver Banner, Tuscany, Italy; L'Oreal UNESCO Award for Women in Science (Asia Pacific); SS Bhatnagar Award; and the Basanti Devi Amir Chand Award by the Indian Council of Medical Research. She was elected fellow of the Indian National Science Academy, Delhi; National Academy of Sciences (India), Allahabad; Indian Academy of Sciences, Bangalore; National Academy of Medical Sciences (India); Royal College of Pathology; and the Academy of Sciences for the Developing World (TWAS). She was conferred an honorary D.Sc. by Pierre and Marie Curie University, Paris.
Kathy Niakan obtained a B.Sc. in Cell and Molecular Biology and B.A. in English Literature from University of Washington, a Ph.D. at University of California, Los Angeles and undertook postdoctoral training with Kevin Eggan at Harvard University. She was a Centre for Trophoblast Research Next Generation Research Fellow at the University of Cambridge. She is currently a group leader at the Francis Crick Institute in London where her lab investigates the mechanisms that direct cell fate in human embryos and stem cells. She was the first scientist in the world to use CRISPR/Cas9 genome editing techniques to study gene function in human embryos. She used these techniques to discover the role of a key gene in human embryo development. Research equipment and objects from her lab have been exhibited at the Science Museum in London. In 2016, Niakin was named as one of Time Magazine’s 100 Most Influential People, Nature Journal’s “Ones to Watch,” Guardian Newspaper’s “Rising Stars,” and The Evening Standard London's most influential people in medicine.
Dianne Nicol is a professor of law at the University of Tasmania in Australia and director of the Centre for Law and Genetics (CLG), which is housed in the Law Faculty. The broad theme of the CLG’s research is the regulation and governance of biotechnology, human genetics and genomics and stem cell technology. Nicol’s current research focuses primarily on the regulation and governance of personalized medicine, biobanking, genome editing and other emerging technologies, together with commercialisation of biotechnology and patenting of biotechnological inventions. She has held a number of Australian Research Council (ARC) discovery grants and currently leads two ARC funded projects, one on the legal, research ethics and social issues associated with genomic data sharing and the other on the regulation of innovative health technologies. Nicol also holds the role of Chair of Academic Senate at the University of Tasmania. She is currently a member of the Steering Committee for the Australian Government’s Genomics Futures Mission. She has also been a member of two principal committees of the Australian National Health and Medical Research Council, the Australian Health Ethics Committee and the Embryo Research Licensing Committee in the triennium from 2015 to 2018 and the Gene Technology Ethics and Community Consultative Committee of the Office of the Gene Technology Regulator from 2017 to 2018. She is a fellow of the Australian Academy of Law.Helen O’Neill is a Lecturer in Reproductive and Molecular Genetics in University College London at the Institute for Women’s Health. After completing her BSc in molecular genetics at University College Cork in Ireland, she went on to do her MSc in Prenatal Genetics and Fetal Medicine at University College London. Helen did her PhD and postdoctoral research in the Department of stem cell biology and developmental genetics at the National Institute for Medical Research, UK. There, she researched the genes involved in sex determination, including genes crucial for the formation of ovaries. Helen is currently in the embryology, IVF and reproductive genetics group where her research focuses on preimplantation embryo development and the use of genome editing to assess the treatment and understanding of disorders. She is Programme Director for the MSc in Reproductive Science and Women’s Health and lectures both masters and medical students. She has written about and been involved in several public debates about the uses of genome editing in humans.
Duanqing Pei,* Ph.D., is Professor and Director General of Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences. He is the founding executive director of the newly established Guangzhou Regenerative Medicine and Health Guangdong Laboratory.
Pei joined the Medical Faculty at Tsinghua University in Beijing China in 2002 and moved to the newly formed Guangzhou Institutes of Biomedicine and Health in 2004. Prior to this appointment, he served as a faculty member at the University of Minnesota School of Medicine. Pei studied the transcription regulation of hepatitis B virus (HBV) for his Ph.D. thesis and worked on extracellular matrix remodeling as a postdoctoral fellow and faculty member.
Upon returning to China, he started to work on stem cell pluripotency first and then reprogramming. The Pei lab in Tsinghua began to publish on the structure and function of Oct4, Sox2, FoxD3, Essrb, and Nanog, and their interdependent relationship towards pluripotency. The Pei lab was the first in China to create iPSCs using a non-selective system, and then improved the iPS process systematically. The Pei lab subsequently disseminated the iPS technology in China by providing not only resources, but also training workshops. His lab demonstrated that fate switching between mesenchymal to epithelial cells, EMT-MET, is essential in both reprogramming and differentiation; vitamin C acts through DNA and histone demethylases to remove epigenetic barriers in reprogramming cells during iPSC generation; and a simple open/close mechanism that governs the chromatin accessibility dynamics associated with both Yamanaka and chemical induction of pluripotency (YIP and CIP). Besides basic research, he has strong interest in translational research. His lab has used ZFNs initially, then Talen, and CRISPR to correct mutations in stem cells with hope to cure diseases through the combined approach of gene editing and stem cell technology. Now, his lab continues to explore new ways to understand and manipulate cell fate, utilize this cutting edge technology to cure diseases. Pei obtained his Ph.D. from the University of Pennsylvania in 1991 and trained as a postdoctoral fellow at the University of Michigan.
Matthew Porteus,* M.D., Ph.D., is an associate professor in the Department of Pediatrics and Institute of Stem Cell Biology and Regenerative Medicine the Child Health Research Institute at Stanford. He graduated magna cum laude from Harvard University with a degree in “History and Science” for which he wrote his undergraduate thesis on social dimensions of the recombinant DNA controversy in the early 1970’s. He then received his M.D./Ph.D. degrees from Stanford University. He completed his pediatric residency training at Boston Children’s Hospital at Harvard and then his specialty training in pediatric hematology/oncology at Boston Children’s Hospital/Dana Farber Cancer Institute. He completed a post-doctoral research fellowship at the California Institute of Technology under the mentorship of Nobel Laureate Dr. David Baltimore. His clinical interests on the Pediatric Stem Cell Transplant Service are to develop improved methods of curing patients with genetic diseases using stem cell based therapies as well as reducing the complications from allogeneic stem cell transplants. His laboratory research focus is on developing genome editing as an approach to cure disease particularly those of the blood but also of other organ systems as well. His research program has made important discoveries in advancing the field of genome editing including the first use of genome editing using engineered nucleases in human cells and optimizing the use of the CRISPR/Cas9 system in primary human stem cells. His goal is to combine his research and clinical interests to bring innovative curative therapies to patients. He served on the U.S. National Academies of Sciences, Engineering, and Medicine’s study committee on human genome editing.
Renzong Qiu, Ph.D., is Professor Emeritus of Institute of Philosophy and Honorary Director, Centre for Applied Ethics, Chinese Academy of Social Sciences; Chair, Academic Committee, Center for Bioethics, Chinese Academy of Medical Sciences/Peking Union Medical College; Professor and Director, Center for Bioethics, Central China University of Science and Technology; Professor and Director, Institute of Bioethics/Center for Ethics and Moral Studies, Renmin University of China; Vice President of Chinese Society for Bioethics; Lifetime member of Kennedy Institute of Ethics, Georgetown University; Fellow of the Hastings Center; and member of the International Institute of Philosophy. Qiu is the former vice-president of Ethics Committee, Ministry of Health; former member of the Expert Committee on Health Policy and Governance and of the Expert Committee on HIV/AIDS Prevention and Control, MOH; former member of the board of directors, International Association of Bioethics; former president of the Asian Bioethics Association; former member of UNESCO’s International Bioethics Committee; and former member of the UNAIDS Reference Group on AIDS and Human Rights. He is the recipient of the 2002 World Network of Technology Award in ethics; the 2009 UNESCO Avicenna Prize of Ethics of Science; and the 2011 Henry Knowles Beecher Award. He is the author of 25 books including Bioethics, Reproductive Health and Ethics (3 volumes); Patient’s Rights (as co-author); AIDS, Sex and Rights, Biomedical Research Ethics (as co-author); Bioethics: Asian Perspectives – A Quest for Moral Diversity (in English), Introduction to Bioethics (as co-author); and Public Health Ethics (as co-author). He is editor of the book series on bioethics and ethics of science and technology (Chinese Social Sciences Press) and author of more than 400 articles published in China or in other countries, among which 70 articles are in English. Qiu was born in Suzhou, Jiangsu Province and graduated from School of Liberal Arts, Tsinghua University, Beijing.
Sivaprakash Ramalingam received his Ph.D. degree from University of Madras India. After a short stint working at a pharmaceutical company, Orchid Pharma Ltd, as a research scientist, he pursued his post-doctoral training in the laboratory of gene-editing pioneer and inventor of zinc finger nucleases Professor Chandra at Johns Hopkins University. He was a Maryland Stem Cell Research Fellow from 2010-2012. He joined CSIR-Institute of Genomics and Integrative Biology, New Delhi in 2017 as a Senior Scientist in the division of genomics and molecular medicine. Ramalingam’s research interests involve identification of fetal hemoglobin associated genetic variants/modifiers including non-coding variants such as miRNAs and lncRNAs for disease severity of sickle cell disease (SCD) and β-thalassemia phenotype using genomic technologies and reactivation of fetal hemoglobin synthesis targeted genome engineering approach. He has authored over 18 research articles in peer-reviewed journals, and receives grant support from various funding agencies in India.
S. R. Rao, Senior Adviser, Department of Biotechnology (DBT), Ministry of Science and Technology, Government of India, received his Ph.D in mycology and plant pathology from the Indian Agricultural Research Institute, New Delhi. Rao was visiting scientist in Tottori University, Japan and at Waite Agricultural Experimental station, Adelaide, Australia and has specialized in molecular pathology. He has served in various positions in Department of Biotechnology, Ministry of Science and Technology, Government of India since 1989 and was actively involved in several sophisticated biotech infrastructure facilities and research resources and in forging bilateral collaboration with Asian and European countries, the introduction of Golden Rice for research in India, new beginnings in veterinary biotechnology, biosecurity systems, formulation of national biotechnology policies, and in strategic planning and investment matters. He served/serves as member of several technical committees of the Government of India and on academic/research councils of universities/institutions. Currently, he is responsible for regulation of genetically engineered products as Scientific Member Secretary of the Review Committee on Genetic Manipulation (RCGM) statutory body. The RCGM became operational for scientific risk assessment and management under India’s Environmental Protection Act 1986. Rao is a member of Genetic Engineering Appraisal Committee (GEAC), a statutory body for environmental release of Living Modified Organisms (LMOs) and chairman of “Scientific Panel on GM Foods” of the Food Safety Standards Authority of India (FSSAI) dealing with risk assessment of imported of genetically modified foods.
Rao specializes in core and cross-sectoral policy issues of biotechnology policy, development, regulation, safety, biosecurity, public private partnerships, international relations and biotech R&D innovation and development, and public concerns and consensus building. He is founder and editorial board member of Asian Biotechnology Development Review (ABDR) and has published more than 40 research papers in national/international journals and made several presentations in various national and international conferences. His current work is focused on formulating a national policy and regulatory framework on bio-innovations through genome editing technology and on reforms in agriculture, food, and biopharma regulations and infrastructure.
Pak C. Sham studied medicine at Cambridge and Oxford Universities and trained in psychiatry at the Bethlem Royal and Maudsley Hospitals. In 2000, he was appointed Professor of Psychiatric and Statistical Genetics at King’s College London. In 2006, he joined the Unuversity of Hong Kong as Chair Professor of Paychiatric Genomics. His research focus on the genetics of common disorders, including, but not exclusively, psychiatric disorders. Sham has also developed commonly used statistical methodologies for analysing genetic data.
John Skehel,*Ph.D., has been a leader in virology research for over 30 years and has provided major insights into the molecular basis of how viruses recognize and infect their host cells. Skehel focuses on the virus that causes influenza, of which there are 3 million to 5 million cases a year worldwide, resulting in up to 500,000 deaths.
Skehel headed the World Health Organization Collaborating Centre for Reference and Research on Influenza between 1975 and 1993 and was the director of the National Institute for Medical Research from 1987-2006. His pioneering research was recognized in 1996 when he received a knighthood. Skehel is a fellow of the U.K.'s Academy of Medical Sciences and the Royal Society.
Margaret Sleeboom-Faulkner is Professor of Social and Medical Anthropology at the University of Sussex (Brighton, UK). Her work focuses on East Asia, in particular on processes of nation-state building in China and Japan; academia and the nation-state; and, biotechnology and society in East Asia. Her most recent book is entitled Global Morality and Life Science Practices in Asia – Assemblages of Life (Palgrave MacMillan, 2014).
Masako Takuma received a M.S. in biology from Chiba University in 1990. She worked for the NIKKEI media company as a science writer, and eventually became an editor and writer in NIKKEI SCIENCE, the Japanese edition of Scientific American. Over a 20 year career as a writer and editor, she has written about biotechnology, medical science, and clinical medicine.
After joining Miraikan in 2011, she organized a team to develop and perform programs to introduce visitors to cutting edge technologies and discuss how to use these new technologies in the future. Since 2016, her team has focused on genome editing technology as applied to human germline cells. They have conducted various types of activities on this topic. Some were for junior high school, high school and university students and others were for citizens. The activities provide opportunities for participants to hear patients’ opinions about severe genetic diseases, and also to share opinions with a member of a governmental committee discussing usage rules for the technologies.
Patrick Tam,* Ph.D., is deputy director and head of the Embryology Research Unit, Children's Medical Research Institute; senior principal research fellow of National Health and Medical Research Council (NHMRC) of Australia; Professor, School of Medical Sciences, Faculty of Medicine and Health, University of Sydney; and Mok Hing-Yiu Distinguished Visiting Professor, School of Biomedical Sciences, University of Hong Kong.
Tam's research focuses on the systems-based investigation of the gene regulatory network underpinning the cellular and molecular mechanisms of body patterning during mouse development and the biology of stem cells. He pioneered the application of micromanipulation and embryo culture for analyzing mouse embryos and examining the development of the head and embryonic gut. The embryological analysis undertaken by his team at CMRI has enabled the construction of a series of fate-maps revealing the organization of the basic body plan of the early embryo. The in-depth knowledge of cell differentiation during early embryogenesis laid the foundation for directing the differentiation of stem cells into clinically useful cell types for therapy in regenerative medicine.
Tam is an editor of Development and a member of the editorial board of journals of developmental biology including Developmental Biology, Developmental Cell, Developmental Dynamics, Differentiation and Genesis. He was a guest editor of Cold Spring Harbor Perspectives in Biology, BioEssays, and Current Opinion of Genetics and Development. He co-edited, with Janet Rossant, the Mouse Development (Academic Press, 2002) and, with James Nelson and Janet Rossant, Mammalian Development (Cold Spring Harbor Laboratory Press, 2013). Tam is a member of the Embryo Research Licensing Committee of the NHMRC of Australia. He serves presently as chair of the scientific advisory committee of Stem Cell Australia and on the scientific advisory board of the School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, University of Hong Kong, and previously the scientific council of RIKEN Centre for Developmental Biology, and scientific advisory board of Max Planck Institute for Molecular Genetics and Eskitis Institute for Drug Discovery. In recognition of his professional accomplishment, Tam was awarded the President’s Medal of the Australia and New Zealand Society of Cell and Developmental Biology, and elected to the Fellowship of the Institute of Biology, the Australian Academy of Science, the Australian Academy of Health and Medical Sciences, the Royal Society of Biology and the Royal Society in London.
Dr Clara Tang obtained her PhD in statistical genetics from the University of Hong Kong in 2010 and received her postdoctoral training in asthma genetics and bioinformatics at the QIMR Berghofer Medical Research Institute, previously known as Queensland Institute of Medical Research (QIMR). She joined the Department of Surgery in 2013 and is currently a Research Assistant Professor.
Her research interest is on elucidating the genetic basis of complex diseases, including cardiovascular diseases and congenital disorders, such as Hirschsprung disease (HSCR) and congenital heart diseases. Through genome-wide association and copy number analyses, Dr Tang and colleagues successfully identified novel common and rare genetic variants predisposing to HSCR, blood lipid levels (important risk factors for coronary artery disease) and other congenital disorders. She is currently focusing on identifying family-segregating and/or rare genetic variants with potentially large effects using the next-generation sequencing (NGS) approaches.
Adrian Thrasher is Professor of Paediatric Immunology and Wellcome Trust Principal Research Fellow at the University College London Great Ormond Street Institute of Child Health (UCL GOSICH) and Honorary Consultant Paediatric Immunologist at Great Ormond Street Hospital for Children National Health Service Foundation Trust (GOSH). He is the Program Head of Infection, Immunity, and Inflammation, and Theme Leader of the Gene Stem and Cellular Therapies theme of the Biomedical Research Centre, at UCL GOSICH/GOSH. He has a long standing research and clinical interest in the development and application of gene therapy, is Director of the Clinical Gene Therapy Program, and PI on several clinical trials for immunodeficiency.
Thrasher’s clinical interests are the diagnosis and treatment of patients with primary immunodeficiency. His specialist interests are in the Wiskott-Aldrich Syndrome (WAS), disorders of innate immunity, and Autoimmune Lymphoproliferative Syndrome. His team at UCL GOSICH/GOSH are conducting trials of somatic gene therapy for various forms of PID including SCID-X1, CGD, ADA-SCID, and WAS. Research interests include the pathophysiology of primary immunodeficiency syndromes especially WAS, the actin cytoskeleton in haematopoietic cells, the development of somatic gene therapy, and thymus transplantation.
Lap-Chee Tsui is President of the Academy of Sciences of Hong Kong, President, Victor and William Fung Foundation (HK), and Director, Qiushi Academy for Advanced Studies, Zhejiang University, Hangzhou.
Born in Shanghai and raised in Hong Kong, Tsui is known for his research in molecular genetics and his contribution to university education.
He received international acclaim in 1989 when he identified the defective gene that causes cystic fibrosis, which is a major breakthrough in human genetics. He has also made significant contributions to the study of the human genome, especially the characterization of chromosome 7, and, identification of additional disease genes. His work paved the Human Genome Project and the HapMap Project. His early research involved the assembly pathway of the bacteriophage lambda and regulation of crystallin gene expression in mammalian lens. He has 300 peer-reviewed scientific publications and 65 invited book chapters and papers.
Tsui was the fourteenth Vice-Chancellor of the University of Hong Kong (HKU). During his tenure from September 2002 to March 2014, he led HKU through a series of unprecedented governance and management reforms, human resource reforms, and strategic developments in research, teaching and learning, and knowledge exchange with society. Tsui had devoted himself to building a strong HKU Family, garnering support from university members, including alumni and friends. Also instrumental to the University's recent development was his tireless effort in encouraging philanthropy for higher education in the community.
Prior to his appointment at HKU, Tsui was Geneticist-in-Chief and Head of the Genetics and Genomic Biology Program of the Research Institute, at The Hospital for Sick Children in Toronto. He was also the holder of the H.E. Sellers Chair in Cystic Fibrosis and University Professor at the University of Toronto.
Tsui has served on the editorial boards of 24 international peer-reviewed scientific journals, numerous scientific review panels, and many national and international advisory committees. He received honorary doctoral degrees from University of King's College, University of New Brunswick, The Chinese University of Hong Kong, St. Francis Xavier University, York University, Tel Aviv University, University of Toronto, University of Aberdeen, King's College London, University of Edinburgh, Fudan University and The University of Western Ontario.
Tsui is a Justice of the Peace of the Hong Kong Special Administrative Region Government and has received the Order of Canada (Officer), the Order of Ontario, Knight of the Légion d'Honneur of France, and the Gold Bauhinia Star (of HKSAR).
Ayo Wahlberg is Professor MSO at the Department of Anthropology, University of Copenhagen. Working broadly within the field of social studies of medicine, his research has focused on traditional herbal medicine (in Vietnam and the United Kingdom), selective reproductive technologies (in China and Denmark) as well as health metrics (in clinical trials and global health). He is the author of Good Quality – The Routinization of Sperm Banking in China; Co-editor of Southern Medicine for Southern People – Vietnamese Medicine in the Making; and Associate Editor at the interdisciplinary journal BioSocieties. He is currently leading a 5-year European Research Council grant project entitled "The Vitality of Disease – Quality of Life in the Making" (2015-2020).
Xiaomei Zhai,* Ph.D., is executive director of the Centre for Bioethics, Chinese Academy of Medical Sciences, and Professor and Director of the Department of Social Sciences and the Humanities, Peking Union Medical College. She is also a fellow at the Hastings Center, the Center for Bioethics at the Renmin University of China, and the Center for Bioethics at the Huazhong University of Science and Technology. Zhai serves as the deputy director of Medical Ethics Committee of the National Health Commission of the Peoples’ Republic of China; as a member of the Expert Committee on Human Organ Donation and Transplantation in China; and as a member and vice chair of the Ethics Group of Chinese Society of Medical Genetics. She is a member of the National Consultation Committee of Experts for Immunization Program; a member of the Expert Committee of the Chinese Marrow Donor Program; President of Society for Bioethics at the Chinese Society for Dialectics of Nature, Philosophy of Nature, Science and Technology; Deputy Chair of the Beijing Medical Ethics Committee of Chinese Medical Association; and Deputy Chair of the Beijing Health Law Society. She serves as a member of editorial board of journals such as Chinese Medical Ethics, British Medical Journal (Chinese version), and Medicine and Philosophy. She has published books including Dying with Dignity, Medical Ethics (as Vice Editor-in-chief), An Introduction to Bioethics (as Co-editor-in-chief), and Public Health Ethics as well as a number of articles and papers on clinical ethics, research ethics, and public health ethics. She served as a member of the Human Genome Organization’s Ethics Committee and as the vice president of the Asian Association of Bioethics.
Feng Zhang is a molecular biologist focused on developing tools to improve human health. He played an integral role in the creation of two revolutionary technologies, optogenetics and CRISPR-Cas9 genome editing. Current research in the Zhang laboratory is centered on the discovery of novel biological systems and processes that can be developed into the next generation of molecular tools and therapies to study and treat human disease. Zhang is a core member of the Broad Institute, an Investigator at the McGovern Institute for Brain Research, the James and Patricia Poitras Professor of Neuroscience at the Massachusetts Institute of Technology (MIT), an associate professor in the departments of Brain and Cognitive Sciences and Biological Engineering at MIT, a Howard Hughes Medical Investigator, and a New York Stem Cell Foundation-Robertson Investigator. He is also a member of the National Academy of Sciences and the American Academy of Arts and Sciences.
Joy Y. Zhang is Senior Lecturer/Associate Professor in Sociology at University of Kent (UK). Originally trained as a medical doctor, Zhang obtained her Ph.D. in Sociology from the London School of Economics and Political Science. She takes on an interdisciplinary approach and investigates the transnational governance of scientific uncertainty. Her articles have appeared in high impact sociology journals such as Sociology, Global Network, Environmental Politics as well as in prestigious natural science journals such as Nature and EMBO Reports. Zhang’s work has fed into the policy making of the Royal Society in the UK and China’s National Health and Family Planning Commission and Ministry of Science and Technology. She is the author of two books: The Cosmopolitanization of Science: Stem Cell Governance in China (2012) and Green Politics in China: Environmental Governance and State-Society Relations (2013). Zhang led the Economic and Social Research Council (ERSC) project, “Governing Accountability in China’s Life Sciences.”
*Member of the Summit Organizing Committee